Stat

DM245 is an EPAC1 activator and STAT3 phosphorylation inhibitor. It effectively increases Rap1-GTP levels through selective activation of EPAC1, without affecting EPAC2 or PKA. DM245 mitigates IL-6/IL-6Rα-mediated STAT3 phosphorylation in endothelial cells and inhibits the TGF-β1-induced transition of fibroblasts to myofibroblasts, leading to decreased levels of αSMA and Collagen I. Importantly, DM245 shows minimal cytotoxicity in normal human lung fibroblasts, indicating a high safety profile for extended exposure.

STAT3-IN-26 is a selective ligand for the transcription factor STAT3, a critical regulator of cell growth and survival. This compound is instrumental in the synthesis of PROTACs (Proteolysis-targeting chimeras) aimed at inducing the degradation of STAT3. It is particularly relevant for research into targeted cancer therapies and studies on cellular signaling pathways involving STAT3.

PROTAC STAT3 degrader-3 (S3D1) targets the STAT3 protein through a PROTAC-mediated degradation mechanism. This compound exhibits potent anticancer activity by facilitating the ubiquitination and subsequent proteasomal degradation of STAT3, a key oncogenic transcription factor. It is primarily applied in research focused on cancer biology, particularly in studies investigating the therapeutic potential of targeting the STAT3 signaling pathway.

(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.

YN11 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) with a Kd of 11.9 μM. By directly binding to the SH2 domain, YN11 effectively inhibits the phosphorylation of STAT3, leading to decreased expression of downstream target proteins. This compound has demonstrated significant biological activity, inducing cell cycle arrest and promoting apoptosis in prostate cancer cells, while also inhibiting cell invasion and migration. In vivo studies indicate that YN11 suppresses tumor growth in prostate cancer xenograft models without causing significant body weight loss or histopathological changes in major organs, making it a valuable tool for research in prostate cancer therapy.

Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury